6F3G

IRAK4 IN COMPLEX WITH inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.37 Å
  • R-Value Free: 0.314 
  • R-Value Work: 0.290 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.

Degorce, S.L.Anjum, R.Dillman, K.S.Drew, L.Groombridge, S.D.Halsall, C.T.Lenz, E.M.Lindsay, N.A.Mayo, M.F.Pink, J.H.Robb, G.R.Scott, J.S.Stokes, S.Xue, Y.

(2018) Bioorg. Med. Chem. 26: 913-924

  • DOI: 10.1016/j.bmc.2018.01.008
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • We have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design. Efforts to tackle low permeability and high efflux in our previously reported pyrrolopyrimidine series ...

    We have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design. Efforts to tackle low permeability and high efflux in our previously reported pyrrolopyrimidine series (Scott et al., 2017) led to the identification of pyrrolotriazines which contained one less formal hydrogen bond donor and were intrinsically more lipophilic. Further optimisation of substituents on this pyrrolotriazine core culminated with the discovery of 30 as a promising in vivo probe to assess the potential of IRAK4 inhibition for the treatment of MyD88 mutant DLBCL in combination with a BTK inhibitor. When tested in an ABC-DLBCL model with a dual MyD88/CD79 mutation (OCI-LY10), 30 demonstrated tumour regressions in combination with ibrutinib.


    Organizational Affiliation

    Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom.,Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg SE-431 83, Mölndal, Sweden.,Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.,Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom. Electronic address: sebastien.degorce@astrazeneca.com.,Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Interleukin-1 receptor-associated kinase 4
A
295Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
Find proteins for Q9NWZ3 (Homo sapiens)
Go to Gene View: IRAK4
Go to UniProtKB:  Q9NWZ3
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Interleukin-1 receptor-associated kinase 4
B
295Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
Find proteins for Q9NWZ3 (Homo sapiens)
Go to Gene View: IRAK4
Go to UniProtKB:  Q9NWZ3
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
CJN
Query on CJN

Download SDF File 
Download CCD File 
A, B
~{N}4,~{N}4-dimethyl-~{N}1-(5-propan-2-ylpyrrolo[3,2-d]pyrimidin-4-yl)cyclohexane-1,4-diamine
C17 H27 N5
ODGACFGAGYOOJS-HDJSIYSDSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
A, B
L-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A, B
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.37 Å
  • R-Value Free: 0.314 
  • R-Value Work: 0.290 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 87.512α = 90.00
b = 110.277β = 90.00
c = 142.133γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
BUSTERrefinement
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-05-23
    Type: Initial release